jinghui xie | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Mr. jinghui xie | Molecular Biology | Best Researcher Award 

Associate professor, at xinjiang medical university, China.

Dr. Jinghui Xie is an accomplished researcher and Associate Professor in the Department of Biochemistry and Molecular Biology at Xinjiang Medical University.  He holds a Doctor of Science (Ph.D.) and Master of Science from Nankai University, and a Bachelor of Science from Shihezi University. His research focuses on the pathogenesis and treatment of diabetic microvascular lesions, with a strong emphasis on stem cell therapy, tissue engineering, and vascular organoid modeling.  Dr. Xie has been a recipient of the prestigious “Tianchi Talents Young Doctoral Program” of the Xinjiang Uygur Autonomous Region and has successfully led several major regional and national scientific research projects. 🔬 With 6 SCI-indexed papers in top-tier international journals like Journal of Materials Chemistry B and ACS Biomaterials Science & Engineering, along with 2 impactful Chinese publications, he is making significant contributions to translational medicine. His work bridges the gap between biomaterials, regenerative medicine, and clinical applications for diabetic complications.

Professional Profile

Google Scholar

🎓 Education

Dr. Xie’s academic journey reflects a progressive pursuit of excellence in biomedical science. 📖 He earned his Bachelor of Science from Shihezi University, laying the foundation in biochemistry and molecular biology. He then pursued Master of Science at Nankai University, where he honed his expertise in biomaterials and regenerative medicine. 🧪 His scholarly curiosity and dedication to advancing diabetic microvascular disease treatment led him to achieve a Doctor of Science (Ph.D.) in Biochemistry and Molecular Biology at Nankai University. During his Ph.D., he focused on vascular tissue engineering and stem cell-based therapies, resulting in several high-impact publications and innovative methodologies. 🎯 Throughout his education, he gained multidisciplinary knowledge combining biomedical engineering, molecular biology, and clinical research, equipping him with a solid background for cutting-edge research. 🎓💡

💼 Experience

Dr. Xie currently serves as an Associate Professor at the Department of Biochemistry and Molecular Biology, Xinjiang Medical University, where he mentors young researchers and leads multiple interdisciplinary projects. 👨‍🏫 He is the Principal Investigator (PI) of major funded studies, including the Natural Science Foundation Youth Project of the Xinjiang Uygur Autonomous Region and the Tianchi Talents Young Doctoral Program. 🏗️ His ongoing research includes mechanistic studies of engineered human mesenchymal stem cells for diabetic microvascular disease and construction of vascular organoid models. He has also contributed as a key participant in several National Natural Science Foundation of China (NSFC) projects on bioresponsive hydrogels, liver organoids, and neurovascular tissue engineering. 🔬 Beyond research, Dr. Xie actively contributes to academic development through teaching, curriculum improvement, and editorial roles in medical education journals. 🏅

🔬 Research Interests

Dr. Xie’s research is deeply rooted in regenerative medicine, biomaterials, and vascular biology. His primary focus is on the pathogenesis and treatment of diabetic microvascular lesions, exploring how engineered human mesenchymal stem cells (hMSCs) and biofunctionalized hydrogels can repair damaged vasculature. 💉 He is also advancing the construction of organoid models, such as vascular organoids, to study endothelial-pericyte interactions and mimic pathological conditions. 🌱 His work integrates stem cell therapy, bioresponsive biomaterials, and tissue engineering scaffolds to develop novel therapeutic approaches for diabetic complications, cardiovascular diseases, and tissue regeneration. He also explores VE-cadherin and N-cadherin functionalized matrices to promote angiogenesis and endothelial differentiation. 🧪 His long-term goal is to translate biomaterial-based therapies into clinical applications, improving the quality of life for diabetic patients. 🌟

🏆 Awards & Honors

Dr. Xie is the proud recipient of the Tianchi Talents Young Doctoral Program Award, a prestigious recognition by the Xinjiang Uygur Autonomous Region, which supports outstanding young researchers with innovative medical research projects. 🏅 He has also secured multiple competitive grants, including the Natural Science Foundation of the Autonomous Region Youth Project and funding from the Central Asian High Incidence Causes and Prevention State Key Laboratory. 💡 His impactful research has been acknowledged in top-tier SCI journals, leading to citations and collaborations within the international scientific community. 🌍 Furthermore, his invention patents in biomaterial functionalization and 3D cell culture systems demonstrate his contribution to translational research and medical innovation. 🚀

📚 Top Noted Publications 

Dr. Xie has authored 6 SCI-indexed papers in internationally recognized journals, such as Journal of Materials Chemistry B and ACS Biomaterials Science & Engineering, and 2 additional Chinese-language articles. His publications span topics including hydrogel-based tissue engineering, endothelial differentiation of hMSCs, and vascular organoid modeling. 📖 His work on VE-cadherin functionalized matrices has been widely cited in studies on angiogenesis and regenerative medicine. ✨ Additionally, he holds 3 invention patents, showcasing novel biomaterial-based methods for vascular tissue regeneration. His research contributions have been cited in applied biomaterials, cardiovascular therapy, and diabetes-related tissue engineering studies, reinforcing his influence in the field. 🌐

🔗 Representative Publications with Citation Prompt

📄 1️⃣ Lv C, Li S, Sang M, Cui T, Xie J.
Title: Construction of Microsphere Culture System for Human Mesenchymal Stem Cell Aggregates
Journal: International Journal of Molecular Sciences
Year: 2025, Volume 26, Article 6435
Link: 🔗 Read Here
Citation Context: Frequently cited in organoid culture system research for its innovative approach to MSC aggregate formation.

📄 2️⃣ Jinghui Xie, Xiaoning Li, Yan Zhang, et al.
Title: VE-Cadherin based matrix promoting self-reconstruction of proangiogenic microenvironment
Journal: Journal of Materials Chemistry B
Year: 2021, 9(1), pp. 3357–3370
Link: 🔗 Read Here
Citation Context: Referenced in endothelial differentiation studies exploring angiogenic microenvironments.

📄 3️⃣ Yuanning Lyu, Jinghui Xie, Yang Liu, et al.
Title: Injectable Hyaluronic Acid Hydrogel for Myocardial Repair
Journal: ACS Biomaterials Science & Engineering
Year: 2020, 6(12), pp. 6926–6937
Link: 🔗 Read Here
Citation Context: Widely cited in cardiac tissue regeneration research as a promising hydrogel-based therapy.

📄 4️⃣ Yang Jun, Xie Jinghui, Gao Chao, et al.
Title: VE-cad-Fc Functionalized Hyaluronic Acid Hydrogel
Journal: Journal of Tianjin University
Year: 2019, 52(1), pp. 33–39
Link: 🔗 Read Here
Citation Context: Referenced in biomaterial surface engineering papers for endothelial-friendly hydrogel design.

📄 5️⃣ Chao Gao, Yan Zhang, Jinghui Xie, et al.
Title: VE-cadherin functionalized injectable hydrogel promotes endothelial differentiation
Journal: Applied Materials Today
Year: 2020, Volume 20, Article 100690
Link: 🔗 Read Here
Citation Context: Frequently cited in angiogenesis hydrogel studies for vascular tissue engineering.

📄 6️⃣ Ke Xu, Chuanshun Zhu, Jinghui Xie, et al.
Title: Enhanced Vascularization of PCL Scaffolds through VEGF-Fc
Journal: Journal of Materials Chemistry B
Year: 2018, 6(6), p. 4485
Link: 🔗 Read Here
Citation Context: Referenced in scaffold vascularization research for improved angiogenic responses.

🏆 Conclusion

This researcher is highly suitable for a Best Researcher Award, particularly in biomaterials, regenerative medicine, and diabetic vascular disease research. Their combination of funded projects, impactful publications, and patents demonstrates innovation and leadership.

Weiwei Fu | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Weiwei Fu | Molecular Biology | Best Researcher Award 

Research assistant professor, at Peking University Third Hospital, China.

Dr. Fu Weiwei is an accomplished medical scientist specializing in gastroenterology and immunology. She currently serves as an Assistant Research Professor and Laboratory Director at the Gastroenterology Department, Peking University Third Hospital, where she leads research at the Beijing Key Laboratory. Dr. Fu earned her Ph.D. in Immunology from Peking University Health Science Center and has a strong foundation in traditional medicine, holding a Bachelor of Medicine from Shandong University. With more than a decade of experience in translational medical research, her work bridges cutting-edge immunological discoveries and practical clinical applications. Her focus lies in immune microenvironment dynamics, gastrointestinal tumor evolution, and the integration of traditional Chinese medicine for digestive disease therapies. She has delivered several high-profile international presentations and has published widely in leading scientific journals. Her contributions have significantly advanced the field of digestive immunology.

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Fu’s academic journey began with a 5-year Bachelor of Medicine program at Shandong University of Traditional Chinese Medicine (2002–2007), where she laid a solid foundation in both conventional and traditional healthcare practices. Her early exposure to integrative medicine inspired a unique perspective on digestive health and immune response. Motivated by scientific rigor, she enrolled in the Combined Master’s and Ph.D. Program in Immunology (2008–2013) at Peking University Health Science Center, mentored by Prof. Wenling Han. This elite program sharpened her skills in molecular biology, immunopathology, and clinical translational research. Throughout her doctoral years, she focused on the host immune responses in cancer, particularly those related to gastric inflammation and tumorigenesis. This diverse academic training enables her to merge modern biomedical technologies with traditional insights, giving her an edge in the multidisciplinary field of digestive immunology.

🧪 Experience

Dr. Fu brings a wealth of research and clinical experience to her current position at the Gastroenterology Department, Peking University Third Hospital (2019–present), where she directs the Beijing Key Laboratory. As an Assistant Research Professor, she leads a team focusing on translational immunology in gastrointestinal diseases. Before this, she completed a prestigious postdoctoral fellowship (2013–2019) at the Tsinghua University Institute of Immunology under Prof. Chen Dong, an Academician of the Chinese Academy of Sciences. During this time, she worked on T-cell signaling, immune checkpoints, and the role of lymphoid cells in cancer. Her lab currently integrates clinical cohort data with multi-omics techniques to explore disease mechanisms. She is also instrumental in mentoring junior researchers and clinicians. Her work bridges laboratory immunology with bedside applications, ensuring scientific advancements are translated into improved diagnosis and therapy for patients.

🔬 Research Interests

Dr. Fu’s research centers on the immune microenvironment in gastrointestinal tumors and digestive tract diseases, such as gastric cancer and inflammatory bowel disease. She applies multi-omics technologies—including single-cell RNA sequencing, proteomics, and microbiome analysis—to decipher host-pathogen interactions and immune cell dynamics during disease evolution. A key aspect of her research is understanding how Helicobacter pylori infection initiates gastric lesions, tumor progression, and immune escape. She also investigates traditional Chinese medicine-based therapies, exploring their role in cancer prevention and immune modulation. Another focal point is early screening and biomarker discovery for precancerous lesions through clinical cohort studies. By integrating high-throughput data with clinical insights, her work aims to improve patient stratification and individualized treatments. Her interdisciplinary approach bridges immunology, oncology, and traditional medicine, placing her at the forefront of gastrointestinal research in China and beyond.

🏆 Awards

Dr. Fu’s scientific excellence has been consistently recognized. She won the Outstanding Paper Award at the 2023 Chinese Medical Association’s National Conference on Digestive Diseases (CGC 2023) for her oral presentation on immune profiling during colorectal cancer progression. Her continuous contributions to clinical immunology, translational oncology, and molecular diagnostics have earned her accolades from both national and international platforms. Her selection as an oral presenter at leading conferences—such as DDW 2024 in Washington, D.C., and UEGW 2023 in Copenhagen—speaks to her international recognition. She has also received patent grants for innovations in inflammation and cancer therapy, reflecting her drive for practical applications. As a dedicated researcher, educator, and innovator, Dr. Fu stands out as a top candidate for award nominations in the fields of biomedical research and clinical translational science.

📚 Top Noted Publications

Dr. Fu has authored and co-authored numerous impactful papers in top-tier journals (JCR Q1–Q3), often as first or corresponding author. Below are select publications with hyperlink.

2025

  1. Luteolin Improves Precancerous Gastric Mucosa by Binding STAT3
    International Journal of Biological Sciences (Q1, IF 8.1)
    📌 Co-Corresponding Author
    🧪 Original Research

  2. CMTM3 Regulates Colitis-Associated Cancer Progression
    Cellular and Molecular Gastroenterology and Hepatology (CMGH) (Q1, IF 7.1)
    📌 Co-Corresponding Author
    🧬 Original Research

  3. Cmtm4 Deficiency Exacerbates H. pylori-Induced Gastric Carcinogenesis
    Pathology International (Q2, IF 2.5)
    📌 Co-Corresponding Author
    🦠 Original Research

  4. The Host Immune Response Landscape in Gastric Cancer Development
    Clinical and Experimental Immunology (Q2, IF 3.4)
    📌 First Author
    🧫 Original Research

2024

  1. Neutrophil Heterogeneity in Hepatocellular Carcinoma and Tumor Immunity
    Cancer Medicine (Q2, IF 2.9)
    📌 Co-First Author
    🔬 Original Research

  2. Oxidative Balance in Diet and Sleep Patterns: A Metabolic Interaction
    Frontiers in Nutrition (Q2, IF 4.0)
    📌 Co-First Author
    🍽 Original Research

  3. CMTM4 Facilitates Gastric Cancer Metastasis via EMT Modulation
    Journal of Gastrointestinal Oncology (Q3, IF 2.0)
    📌 Co-First Author
    🧠 Original Research

  4. Cmtm4 Shapes Colitis Outcomes via Microbial Dysbiosis and Mucosal Immunity
    Journal of Genetics and Genomics (Q1, IF 6.6)
    📌 Co-Corresponding Author
    🧪 Original Research

  5. Serum Proteomics-Based Biomarkers of Precancerous Gastric Lesions
    Frontiers in Molecular Biosciences (Q2, IF 3.9)
    📌 Co-Corresponding Author
    🔍 Original Research

  6. Treg Subsets Orchestrate Tumor Microenvironment in Colorectal Cancer
    Frontiers in Immunology (Q1, IF 5.7)
    📌 Co-First & Corresponding Author
    🧫 Original Research

2023

  1. Helicobacter pylori and Inflammasome Activation in Gastric Pathogenesis (Review)
    Helicobacter (Q2, IF 4.3)
    📌 Co-Corresponding Author
    🧯 Review Article

2022

  • Lymphocyte Profile Alterations in Precancerous Gastric Lesions
    Journal of Leukocyte Biology (Q2, IF 5.5)
    📌 First Author
    🧬 Original Research

  • B7 Family Molecules and Immune Evasion in H. pylori Infection (Review)
    Helicobacter (Q2, IF 4.4)
    📌 Co-Corresponding Author
    🧫 Review Article

Conclusion

Dr. FU Weiwei demonstrates an exceptional and well-rounded profile as a medical researcher with significant contributions to immunology and gastroenterology, supported by prestigious academic training, a robust scientific publication record, impactful patents, and strong conference presence. These achievements, particularly in translational cancer immunology, make Dr. Fu highly suitable for the Best Researcher Award.

King-cheong LAM | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. King-cheong LAM | Molecular Biology | Best Researcher Award

Senior Lecturer, at The School of Professional Education and Executive Development (SPEED), The Hong Kong Polytechnic University, Hong Kong.

Dr. LAM King-cheong Antony is a seasoned academic currently serving as a Senior Lecturer in the Division of Science, Engineering and Health Studies at the College of Professional and Continuing Education (CPCE), The Hong Kong Polytechnic University. With a rich interdisciplinary background in physics and engineering education, Dr. Lam has consistently contributed to innovative teaching methods and research initiatives. His career journey from a secondary school teacher to a respected university lecturer is marked by dedication to student development, academic leadership, and community outreach. 📘 His roles as Programme Leader and Co-Investigator in prestigious funded projects reflect his commitment to applied research and educational advancement. Through his work in nanotechnology, sustainable energy, and smart sensor systems, Dr. Lam exemplifies a professional devoted to shaping the future of science education and technology for sustainable urban living. 🌱

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Antony Lam’s academic path is built on a solid foundation in science and education. 🎓 He earned his Doctor of Philosophy from The Hong Kong Polytechnic University in 2017, where he focused on gas sensing materials using graphene-based composites. Prior to that, he completed his Master of Philosophy (2008) and Bachelor of Science in Physics (2005) at The University of Hong Kong, establishing his grounding in physical sciences. Recognizing the importance of pedagogy in science, he also pursued a Postgraduate Diploma in Education from The University of Hong Kong in 2010, equipping himself with the skills to bridge research and teaching. This rare blend of scientific rigor and educational expertise empowers him to mentor students and lead cross-disciplinary research with confidence. 🧠 His training has laid the foundation for a career devoted to both scientific discovery and academic development.

💼 Experience

Dr. Lam’s professional career spans across secondary and tertiary education sectors. 🏫 From 2007 to 2012, he began his journey as a science teacher at Heung To Secondary School (TKO), where he nurtured young minds with enthusiasm for physics. In 2018, he transitioned to higher education as a Lecturer at CPCE, The Hong Kong Polytechnic University, and was promoted to Senior Lecturer in 2024. Over the years, Dr. Lam has taken on several key academic leadership roles, including Programme Leader for Associate in Engineering and Higher Diploma in Aircraft Services Engineering, and Assistant Programme Leader for the BEng (Hons) in Mechanical Engineering. 💼 These positions not only reflect his pedagogical expertise but also his capability in curriculum innovation and academic governance. Dr. Lam’s dedication to bridging practical engineering with academic training is central to his career mission of advancing applied science education. ⚙️

🔬 Research Interests

Dr. Lam’s research interests lie at the intersection of nanotechnology, green energy, sustainable materials, and smart sensing systems. 🌍 His work explores the fabrication of advanced materials such as tin-based perovskites, graphene composites, and aluminum-ion batteries to enhance energy efficiency and sensor capabilities. A significant part of his research addresses real-world sustainability challenges—ranging from developing natural fiber/concrete composites for eco-friendly buildings to ionic-liquid-based gas sensors for smart cities. 🏙️ He is also actively investigating thermal and mechanical properties of biomaterials, including mycelium-based composites for biomedical applications. His interdisciplinary approach combines physics, chemistry, and engineering to produce applicable technologies for energy and healthcare sectors. Through multiple funded projects and international conferences, Dr. Lam has established himself as a researcher committed to translational science for societal impact. 🌱

🏅 Awards

Dr. Lam’s research excellence has earned him both institutional recognition and competitive external grants. 🏆 In 2023, he received the KML Third Prize (HK$200,000) from the Koo Meng Li and Koo Mi Wen Na Charitable Foundation Limited for his project on natural fiber/concrete composites for sustainable buildings. He has been a Principal Investigator and Co-Investigator in numerous high-impact projects, including a nearly HK$1 million RGC-funded project on mycelium-based insoles for diabetic care. 💰 These awards and grants highlight his innovative work in sustainable technology and material science. Dr. Lam’s recognition not only reflects his technical acumen but also his leadership in building collaborative, real-world solutions. His consistent involvement in cutting-edge research underscores his role as a forward-thinking academic in science and engineering education. 🧪

📚 Top Noted Publications

Dr. Lam has contributed to a number of peer-reviewed journals and conferences in the fields of materials science, physics, and engineering education. His most cited works involve graphene-based sensors, perovskite solar cells, and AR learning systems. 📖 His publication list includes:

1. Ahmed, S. B., Kan, H. W., Lam, K. C., & Yip, C. T. (2025)

Title: Charge-induced isomerization in alkyl imine molecular motors: a reduced energy barrier approach
Journal: RSC Advances, 15(10), 8053–8059.

  • Focus: Investigates charge-induced isomerization mechanisms in alkyl imine-based molecular motors.

  • Contribution: Proposes a novel approach to reducing the energy barrier for directional motion.

  • Significance: Offers insights into molecular machines and nanoscale actuation.

2. Wang, Y. D., et al., incl. Lam, K. C. (2024)

Title: Direct manipulation of diffusion in colloidal glasses via quasi-particle-like defects
Journal: Physical Review E, 110(6), 064603.

  • Focus: Explores defect-driven dynamics in colloidal glasses.

  • Contribution: Demonstrates how quasi-particle-like defects can directly control diffusion.

  • Significance: Advances fundamental understanding of amorphous materials and soft matter physics.

3. Li, K. C., Lam, K. C., et al. (2024)

Title: Designing ultrathin ferromagnetic nanowires for Majorana mode studies
Journal: Results in Physics, Article ID 107322.

  • Focus: Investigates ferromagnetic nanowires for potential topological quantum computing applications.

  • Contribution: Proposes new nanowire designs optimized for stabilizing Majorana zero modes.

  • Significance: Supports progress in solid-state quantum computation.

4. Lo, K., Ng, J., Chau, & Lam, A. (2023)

Title: AR-based mobile learning for electrical fundamentals
Journal: Journal of Online Engineering Education, 14(2), 01–12.

  • Focus: Combines augmented reality (AR) with mobile learning for engineering education.

  • Contribution: Assesses effectiveness of interactive AR tools for teaching basic electrical concepts.

  • Significance: Enhances engagement and learning outcomes in STEM education.

5. Lam, K. C., Huang, B., & Shi, S. Q. (2017)

Title: Room-temperature methane gas sensing with graphene-SnO₂
Journal: Journal of Materials Chemistry A, 5, 11131–11142.

  • Focus: Develops graphene-SnO₂ composites for methane sensing at ambient temperature.

  • Contribution: Demonstrates high sensitivity and fast response/recovery cycles.

  • Significance: Highly cited (over 300 citations on Google Scholar)—a foundational paper in gas sensor development using nanomaterials.

Conclusion

Dr. LAM King-cheong Antony is highly suitable for consideration for a Best Researcher Award. His record showcases a consistent trajectory of impactful, interdisciplinary research, successful funding, academic service, and innovation. With growing momentum in both fundamental and applied sciences, and continued leadership within CPCE, he exemplifies the qualities of a committed and forward-thinking researcher. Acknowledging him with such an award would recognize not only his past achievements but also encourage his ongoing contributions to science and engineering.

Camille EVRARD | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Camille EVRARD | Molecular Biology | Best Researcher Award 

MD-PhD, at Poitiers University Hospital, France.

Dr. Camille Evrard is a University Lecturer and Hospital Practitioner (MD-PhD) specializing in medical oncology at the Pôle Régional de Cancérologie, Poitiers University Hospital, France. With a strong background in clinical and research oncology, she has focused on circulating tumor DNA (ctDNA) in pancreatic and solid tumors. Dr. Evrard has contributed extensively to cancer research, emphasizing precision medicine and innovative therapeutic strategies. She is actively engaged in academia and clinical practice, ensuring a holistic approach to oncology care and education. Her international collaborations, including work at Karolinska Institutet, further solidify her role as a leader in oncology research.

Professional Profile

Scopus

Google Scholar

Education 🎓

Dr. Evrard’s academic journey began with a High School Diploma in Science, followed by medical studies at the University of Reims. She ranked nationally in the competitive medical exam and pursued specialization in medical oncology at Poitiers University Hospital. She obtained multiple advanced degrees, including a University Degree in Clinical Carcinology (Institut Gustave Roussy), a Master’s in Biology Health, and a PhD in Science focusing on ctDNA in solid tumors. Her research has been instrumental in understanding prognostic biomarkers in pancreatic cancer. Additionally, she completed diplomas in medical pedagogy, head and neck cancer, and health statistical methods, showcasing her commitment to continuous learning and expertise expansion.

Experience 💼

Dr. Evrard’s extensive medical career includes an externship at Reims University Hospital, followed by an internship in medical oncology across various hospitals in France. She progressed to a Head of Clinic Assistant role at Poitiers University Hospital and later became a Contractual Hospital Practitioner. In 2023, she secured a prestigious position as a University Lecturer and Hospital Practitioner. Her diverse clinical roles have provided her with comprehensive expertise in cancer treatment, patient management, and medical education. Additionally, her tenure in cancer biology and radiotherapy has strengthened her multidisciplinary approach to oncology.

Research Interests 🌍

Dr. Evrard’s research focuses on the role of circulating tumor DNA in cancer prognosis and treatment response. Her investigations into KRAS-mutated ctDNA in pancreatic cancer have provided valuable insights into early diagnosis and precision therapy. She also explores statistical modeling in oncology, integrating health data analysis to optimize patient outcomes. Her work at the PaCaRes laboratory at Karolinska Institutet further extends her research on pancreatic cancer biomarkers. Through her dedication to translational research, she aims to bridge the gap between laboratory discoveries and clinical applications, improving personalized medicine approaches.

Awards 🏆

Dr. Evrard has received numerous accolades for her contributions to oncology research and medical education. Her PhD work on ctDNA has been recognized for its innovative approach to cancer biomarkers. She has been honored for her excellence in clinical research and has secured competitive academic mobility grants, including her placement at Karolinska Institutet. Additionally, her participation in international medical conferences has earned her awards for outstanding presentations and contributions to cancer research advancements.

Top Noted Publications 📘

The series of studies led by C. Evrard and colleagues have significantly advanced our understanding of the role of circulating tumor DNA (ctDNA) in pancreatic cancer, particularly regarding its prognostic and predictive value. Below is a summary of each study:

  1. “Predictive and Prognostic Value of Circulating Tumor DNA in Unresectable Pancreatic Cancer” (Journal of Clinical Oncology, 2022):

    • Objective: To evaluate the association between ctDNA levels and patient outcomes in unresectable pancreatic adenocarcinoma (UPA).
    • Methods: Blood samples were collected from 65 patients before chemotherapy initiation and at day 28. ctDNA was analyzed using digital droplet PCR to detect KRAS mutations.
    • Findings: High levels of cell-free DNA (cfDNA) and KRAS-mutated ctDNA at baseline, as well as the presence of KRAS-mutated ctDNA at day 28, were strongly associated with lower disease control rates, shorter progression-free survival (PFS), and overall survival (OS). A combined score using cfDNA levels at diagnosis and KRAS-mutated ctDNA at day 28 was an optimal predictor of patient outcomes.
    • Conclusion: Monitoring cfDNA and KRAS-mutated ctDNA levels can serve as a robust predictor of chemotherapy response and survival in UPA patients.

  2. “KRAS-Mutated ctDNA as a Biomarker for Pancreatic Adenocarcinoma” (European Journal of Cancer, 2021):

    • Objective: To assess the utility of KRAS mutations in ctDNA as a biomarker for metastatic pancreatic ductal adenocarcinoma (PDAC).
    • Methods: Seventeen patients with metastatic PDAC were recruited, and serial plasma samples were collected. ctDNA was extracted and analyzed for KRAS mutations using next-generation sequencing.
    • Findings: KRAS mutations were detected in 29.4% of patients. Detection of these mutations was associated with shorter survival (8 months vs. 37.5 months in mutation-negative patients). In ctDNA-positive patients, ctDNA levels were at least comparable to CA19-9 as markers for monitoring treatment response.
    • Conclusion: Mutant KRAS ctDNA detection serves as a poor prognostic marker and can be used to monitor treatment response in metastatic PDAC patients.

  3. “Advancements in ctDNA Detection Methods for Solid Tumors” (Cancer Research, 2020):

    • Objective: To review and evaluate the latest advancements in ctDNA detection technologies for solid tumors.
    • Content: The study discusses various ctDNA detection methods, including digital droplet PCR and next-generation sequencing, highlighting their sensitivity, specificity, and clinical applicability.
    • Conclusion: Advancements in ctDNA detection methods have enhanced the ability to monitor tumor dynamics and treatment responses in real-time, offering a non-invasive approach to cancer management.

  4. “Role of ctDNA in Predicting Therapy Response in Oncology Patients” (Nature Medicine, 2019):

    • Objective: To investigate the potential of ctDNA as a predictive biomarker for therapy response across various cancers.
    • Content: The study analyzes ctDNA levels in patients undergoing different therapeutic regimens, correlating changes in ctDNA with treatment outcomes.
    • Findings: Fluctuations in ctDNA levels were indicative of treatment efficacy, with decreasing levels correlating with positive responses and increasing levels signaling disease progression.
    • Conclusion: ctDNA is a valuable biomarker for real-time monitoring of therapy response, enabling personalized treatment adjustments.

  5. “Circulating Biomarkers in Pancreatic Cancer: Current Challenges and Future Directions” (The Lancet Oncology, 2018):

    • Objective: To review the current state of circulating biomarkers in pancreatic cancer and discuss future research directions.
    • Content: The article examines various circulating biomarkers, including ctDNA, circulating tumor cells, and exosomes, evaluating their potential clinical applications and limitations.
    • Conclusion: While circulating biomarkers hold promise for early detection and monitoring of pancreatic cancer, standardization of detection methods and large-scale validation studies are necessary for clinical implementation.

Conclusion

Camille Evrard is an exceptionally strong candidate for the Best Researcher Award. Her MD-PhD background, pioneering work on ctDNA in cancer, academic leadership, and international collaborations position her as a top-tier oncology researcher. Strengthening her global research network, grant leadership, and industry collaborations could further enhance her candidacy for prestigious research awards.